Author: chris

Aswering the questions just 400 words

 

 

Is intelligence a fixed or malleable human characteristic?  Can the brain change?  Your answer to that question will significantly affect your ability to achieve results.  In 2007, researchers from Stanford University conduced an experiment in which half the students in a school were presented with a lecture describing that the brain is malleable and not fixed.  The other half of the students did not receive this training.  The knowledge that the brain is not fixed but is malleable significantly improved grade points, test performance and morale over students that did not receive the training.  [1].  Wow!

 

The Objectives:

• Develop insight into the brain development of humans.
• Describe the process of neuroplasticity.

 

The Link:

Beautiful Brain  

 

The Questions:

Topic 1- The Science

Please answer these questions in your response:

• What do scientists understand about neuroplasticity of the brain?
• How does the brain change and form new neural connections for people who have had a trauma or illness, or for the aged?

I have Bench to commercialization’s class and the Dr gave us some questions to do the research ( each question should be at least one page) could you please assist me

1. Explain how and why modern biotechnology has evolved. Make sure to provide in your answer

   how biotechnology and pharmaceutical companies differ. Include in your discussion the big

   pharma approach as well as the novel approach employed by biotechnology. Incorporate the 3

   characteristics that describe biotechnology.

2. Discuss the history of how biotechnology partnering strategies evolved. Use Genentech as an

   example.

3. Explain the objectives of the preclinical phase of development. How does a company decide to

   go forward with initiating a clinical trial? What types of communication is necessary with the

   FDA to initiate a Phase I trial?

4. What are the clinical phases of drug development? Provide a summary of the objectives of

   each. Give an example of success at each stage.

5. Provide a detailed discussion of the approval process. Make sure to define and differentiate

   between accelerated approval, fast track status and priority review. What role does the

   advisory committee play?

6. What is the Hatch-Waxman Act and why was it enacted? What does it allow for? How is it

   applicable to generics?

7. What are Orphan Drugs? Why have orphan drugs historically not been the focus of drug

   development in early-stage biotechnology companies?

8. How does a start-up biotechnology company begin? Explain how management teams are

   usually structured

I have Bench to commercialization’s class and the Dr gave us some questions to do the research ( each question should be at least one page) could you please assist me

1. Explain how and why modern biotechnology has evolved. Make sure to provide in your answer

   how biotechnology and pharmaceutical companies differ. Include in your discussion the big

   pharma approach as well as the novel approach employed by biotechnology. Incorporate the 3

   characteristics that describe biotechnology.

2. Discuss the history of how biotechnology partnering strategies evolved. Use Genentech as an

   example.

3. Explain the objectives of the preclinical phase of development. How does a company decide to

   go forward with initiating a clinical trial? What types of communication is necessary with the

   FDA to initiate a Phase I trial?

4. What are the clinical phases of drug development? Provide a summary of the objectives of

   each. Give an example of success at each stage.

5. Provide a detailed discussion of the approval process. Make sure to define and differentiate

   between accelerated approval, fast track status and priority review. What role does the

   advisory committee play?

6. What is the Hatch-Waxman Act and why was it enacted? What does it allow for? How is it

   applicable to generics?

7. What are Orphan Drugs? Why have orphan drugs historically not been the focus of drug

   development in early-stage biotechnology companies?

8. How does a start-up biotechnology company begin? Explain how management teams are

   usually structured

I have Bench to commercialization’s class and the Dr gave us some questions to do the research ( each question should be at least one page) could you please assist me

1. Explain how and why modern biotechnology has evolved. Make sure to provide in your answer

   how biotechnology and pharmaceutical companies differ. Include in your discussion the big

   pharma approach as well as the novel approach employed by biotechnology. Incorporate the 3

   characteristics that describe biotechnology.

2. Discuss the history of how biotechnology partnering strategies evolved. Use Genentech as an

   example.

3. Explain the objectives of the preclinical phase of development. How does a company decide to

   go forward with initiating a clinical trial? What types of communication is necessary with the

   FDA to initiate a Phase I trial?

4. What are the clinical phases of drug development? Provide a summary of the objectives of

   each. Give an example of success at each stage.

5. Provide a detailed discussion of the approval process. Make sure to define and differentiate

   between accelerated approval, fast track status and priority review. What role does the

   advisory committee play?

6. What is the Hatch-Waxman Act and why was it enacted? What does it allow for? How is it

   applicable to generics?

7. What are Orphan Drugs? Why have orphan drugs historically not been the focus of drug

   development in early-stage biotechnology companies?

8. How does a start-up biotechnology company begin? Explain how management teams are

   usually structured

I have Bench to commercialization’s class and the Dr gave us some questions to do the research ( each question should be at least one page) could you please assist me

1. Explain how and why modern biotechnology has evolved. Make sure to provide in your answer

   how biotechnology and pharmaceutical companies differ. Include in your discussion the big

   pharma approach as well as the novel approach employed by biotechnology. Incorporate the 3

   characteristics that describe biotechnology.

2. Discuss the history of how biotechnology partnering strategies evolved. Use Genentech as an

   example.

3. Explain the objectives of the preclinical phase of development. How does a company decide to

   go forward with initiating a clinical trial? What types of communication is necessary with the

   FDA to initiate a Phase I trial?

4. What are the clinical phases of drug development? Provide a summary of the objectives of

   each. Give an example of success at each stage.

5. Provide a detailed discussion of the approval process. Make sure to define and differentiate

   between accelerated approval, fast track status and priority review. What role does the

   advisory committee play?

6. What is the Hatch-Waxman Act and why was it enacted? What does it allow for? How is it

   applicable to generics?

7. What are Orphan Drugs? Why have orphan drugs historically not been the focus of drug

   development in early-stage biotechnology companies?

8. How does a start-up biotechnology company begin? Explain how management teams are

   usually structured

I have Bench to commercialization’s class and the Dr gave us some questions to do the research ( each question should be at least one page) could you please assist me

1. Explain how and why modern biotechnology has evolved. Make sure to provide in your answer

   how biotechnology and pharmaceutical companies differ. Include in your discussion the big

   pharma approach as well as the novel approach employed by biotechnology. Incorporate the 3

   characteristics that describe biotechnology.

2. Discuss the history of how biotechnology partnering strategies evolved. Use Genentech as an

   example.

3. Explain the objectives of the preclinical phase of development. How does a company decide to

   go forward with initiating a clinical trial? What types of communication is necessary with the

   FDA to initiate a Phase I trial?

4. What are the clinical phases of drug development? Provide a summary of the objectives of

   each. Give an example of success at each stage.

5. Provide a detailed discussion of the approval process. Make sure to define and differentiate

   between accelerated approval, fast track status and priority review. What role does the

   advisory committee play?

6. What is the Hatch-Waxman Act and why was it enacted? What does it allow for? How is it

   applicable to generics?

7. What are Orphan Drugs? Why have orphan drugs historically not been the focus of drug

   development in early-stage biotechnology companies?

8. How does a start-up biotechnology company begin? Explain how management teams are

   usually structured

I have Bench to commercialization’s class and the Dr gave us some questions to do the research ( each question should be at least one page) could you please assist me

1. Explain how and why modern biotechnology has evolved. Make sure to provide in your answer

   how biotechnology and pharmaceutical companies differ. Include in your discussion the big

   pharma approach as well as the novel approach employed by biotechnology. Incorporate the 3

   characteristics that describe biotechnology.

2. Discuss the history of how biotechnology partnering strategies evolved. Use Genentech as an

   example.

3. Explain the objectives of the preclinical phase of development. How does a company decide to

   go forward with initiating a clinical trial? What types of communication is necessary with the

   FDA to initiate a Phase I trial?

4. What are the clinical phases of drug development? Provide a summary of the objectives of

   each. Give an example of success at each stage.

5. Provide a detailed discussion of the approval process. Make sure to define and differentiate

   between accelerated approval, fast track status and priority review. What role does the

   advisory committee play?

6. What is the Hatch-Waxman Act and why was it enacted? What does it allow for? How is it

   applicable to generics?

7. What are Orphan Drugs? Why have orphan drugs historically not been the focus of drug

   development in early-stage biotechnology companies?

8. How does a start-up biotechnology company begin? Explain how management teams are

   usually structured

I have Bench to commercialization’s class and the Dr gave us some questions to do the research ( each question should be at least one page) could you please assist me

1. Explain how and why modern biotechnology has evolved. Make sure to provide in your answer

   how biotechnology and pharmaceutical companies differ. Include in your discussion the big

   pharma approach as well as the novel approach employed by biotechnology. Incorporate the 3

   characteristics that describe biotechnology.

2. Discuss the history of how biotechnology partnering strategies evolved. Use Genentech as an

   example.

3. Explain the objectives of the preclinical phase of development. How does a company decide to

   go forward with initiating a clinical trial? What types of communication is necessary with the

   FDA to initiate a Phase I trial?

4. What are the clinical phases of drug development? Provide a summary of the objectives of

   each. Give an example of success at each stage.

5. Provide a detailed discussion of the approval process. Make sure to define and differentiate

   between accelerated approval, fast track status and priority review. What role does the

   advisory committee play?

6. What is the Hatch-Waxman Act and why was it enacted? What does it allow for? How is it

   applicable to generics?

7. What are Orphan Drugs? Why have orphan drugs historically not been the focus of drug

   development in early-stage biotechnology companies?

8. How does a start-up biotechnology company begin? Explain how management teams are

   usually structured

In your second paper (1000 word maximum-two pages), please outline the steps that you would take to bring your novel stem cell discovery from animal preclinical trials to clinical studies involving human subjects. What steps must you take to make the FDA happy with your research?  How do you insure that you conducting the trials ethically? How are you involving the community to keep them aware of your clinical results?

What makes it difficult to study the genes of prokaryotes and properly classify them?